Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
about
Biomarkers for determining the prognosis in chronic myelogenous leukemiaResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsChronic myeloid leukemia: mechanisms of blastic transformationChronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.Does HOXA9 Gene Expression in Egyptian Chronic Myelogenous Leukemia Patients Affect Disease Progression? A Retrospective Cohort Study.The expanding role of nilotinib in chronic myeloid leukemia.Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state.BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.Genetic mechanisms of chronic myeloid leukemia blastic transformation.Cell-penetrating fusion peptides OD1 and OD2 interact with Bcr-Abl and influence the growth and apoptosis of K562 cells.The effect of the additional cytogenetic abnormalities on major molecular response and BCR-ABL kinase domain mutations in long-term follow-up chronic myeloid leukemia patients, a cross sectional study.Long-term molecular response after discontinuation of interferon-alpha in two patients with chronic myeloid leukaemia.Metal chelator TPEN selectively induces apoptosis in K562 cells through reactive oxygen species signaling mechanism: implications for chronic myeloid leukemia.On the persistence of the primitive chronic myeloid leukaemia cell in patients in complete molecular response.
P2860
Q26824660-A068D694-E861-4002-B3C3-4B4350D07A3CQ27028181-CC47E73B-DB5A-44EF-BDDE-1F9AE4F5DFA5Q33968037-E9BFF702-D019-42AC-A790-3E794F0F178DQ36364850-5C0ACC33-449D-415B-B9E0-3AFD6387D5DFQ37418952-DEBCC3FB-14C4-4239-8358-E7A40E659DB0Q37814411-4C6471F5-1FDA-44AC-8A06-BD96322EC7C7Q37836926-FFFC3765-CB61-4225-965A-1E79B9A8B76EQ37974490-E6FD7EBC-2DB8-48EC-8FE2-E5E2F6920544Q37983490-8B298FBC-E5FD-4476-BDDA-7972A157C527Q39087712-157F55C2-26E3-4249-BCD4-473937B1FC5CQ39125138-ACA9E443-84F6-443F-9871-0BAAA4934432Q42343700-2652E6AF-F43A-4BB9-8AA7-6BDA2F4F4ADAQ46383293-06AB6B4A-8F7B-4F9A-BD19-5429DCFB29A8Q55083219-CC91DD4C-A097-4119-885B-F53FB5661AE0
P2860
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Impact of additional chromosom ...... tive chronic myeloid leukemia.
@ast
Impact of additional chromosom ...... tive chronic myeloid leukemia.
@en
Impact of additional chromosom ...... tive chronic myeloid leukemia.
@nl
type
label
Impact of additional chromosom ...... tive chronic myeloid leukemia.
@ast
Impact of additional chromosom ...... tive chronic myeloid leukemia.
@en
Impact of additional chromosom ...... tive chronic myeloid leukemia.
@nl
prefLabel
Impact of additional chromosom ...... tive chronic myeloid leukemia.
@ast
Impact of additional chromosom ...... tive chronic myeloid leukemia.
@en
Impact of additional chromosom ...... tive chronic myeloid leukemia.
@nl
P2093
P2860
P1433
P1476
Impact of additional chromosom ...... tive chronic myeloid leukemia.
@en
P2093
Bernd Dörken
Christiane Bommer
Gökben Koca
Hendrik Nogai
Michaela Schwarz
Peter Daniel
Philipp le Coutre
Seval Türkmen
Theo D Kim
P2860
P304
P356
10.3324/HAEMATOL.2009.014712
P577
2009-12-16T00:00:00Z